NEW
YORK, Oct. 5, 2022 /CNW/ -- Mind Medicine
(MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or
"MindMed"), a clinical stage biopharmaceutical company developing
novel products to treat brain health disorders, today announced
that members of MindMed's management team will participate in the
Cantor Fitzgerald Neurology & Psychiatry Conference, taking
place at the Ritz Carlton, San Francisco,
CA from October 6-7, 2022.
Cantor Fitzgerald Neurology & Psychiatry
Conference
Format: Panel presentation and one-on-one
investor meetings
Panel Title: "Tripping our way to a new treatment paradigm for
psychiatric disorders: intermittent therapy vs chronic
treatment"
Panel Date: Thursday, October 6,
2022
Panel Time: 12:10 p.m. PDT
Location: Ritz Carlton, San Francisco,
CA
About MindMed
MindMed is a clinical stage biopharmaceutical company developing
novel products to treat brain health disorders. Our mission is to
be the global leader in the development and delivery of treatments
that unlock new opportunities to improve patient outcomes. We are
developing a pipeline of innovative drug candidates, with and
without acute perceptual effects, targeting the serotonin,
dopamine, and acetylcholine systems.
MindMed trades on NASDAQ under the symbol MNMD and on the
Canadian NEO Exchange under the
symbol MMED.
For Media: media@mindmed.co
For Investors: ir@mindmed.co
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mindmed-to-participate-in-the-cantor-fitzgerald-neurology--psychiatry-conference-301641526.html
SOURCE Mind Medicine (MindMed) Inc.